Programme

08h30-10h25 Plenary Session
08h30-08h40 Welcome and introduction – Dr Hannes Koornhof
08h40-12h30 Industry-sponsored breakfast symposium (Novartis) – Myeloproliferative neoplasms:
Chair: Dr Jacques Malherbe
08h40-09h25 PMF: To transplant or not, and how does Ruxolitinib influence this decision? – Prof Claire Harrison
09h25-10h10 Difficult clinical scenarios in polycythemia – Prof Claire Harrison
10h10-10h25 Discussion and questions
10h25-10h45 Tea break / Poster viewing
10h45-11h30 The changing treatment landscape or Chronic Myeloid Leukemia (CML) – Prof Guiseppe Saglio
11h30-12h15 “Cure” in CML: From timing of transplant to treatment-free remission – Prof Guiseppe Saglio
12h15-12h30 Discussion and questions
12h30-13h20 Lunch / Poster viewing
13h20-14h30 Proffered papers
Chair: Professor Veron Louw
14h30-17h15 Parallel sessions
14h30-17h15 Session on Acute Leukemia (Sponsored by Abbvie)
Chair: Dr Theo Gerdener
Nurses symposium
Chairs: Sr Rowan Robinson, Sr Eileen Claasens
14h30-15h15 AML in the young: Have we moved past standard “7+3”? – Dr Farhad Ravandi-Kashani
14:30-14:35 Welcome and agenda for the day Eileen Claassens
14:35-14:50 Systemic anti-cancer treatments – an overview Rowan Robinson
14:50-15:05 Chemotherapy Ina Strijbis
15:05-15:20 Targeted therapy – Care of patient receiving Daratumumab Drina Heyns
15:20-15:35 Immunotherapy Pam Chetty
15:35-15:50 Patient assessment Andrea Brummer
15:50-16:05 The effect of Covid-19 on transplant facilities Eileen Claassens
16:05-16:20 The worth of cancer nurses who are Lidia Marais
16:20-16:40 Self-care for the care-giver Kirstie van Blerk
16:40-16:50 Exciting news! Igazi announcement and update Caroline Rich
16:40-16:50 Conclusion, wrap up and thanks Rowan Robinson
15h15-15h35 Tea break / Poster viewing
15h35-16h20 How I treat High risk MDS/AML in the elderly – Dr Farhad Ravandi-Kashani
17h00-17h15 Discussion and questions
17h30 AGM
Dr Hannes Koornhof
19h00 Gala dinner (sponsored by Abbvie)
08h30-12h20 Industry breakfast symposium (sponsored by Janssen)
– Myeloma, Waldenström Macroglobulinemia and Mantle Cell Lymphoma
Chair: Dr Karen Gunther
08h30-09h15 Myeloma with high risk genetics: Available treatment options – Prof Philippe Moreau
09h15-10h00 Newer novel agents and CAR-Ts: Gain vs Cost? – Prof Philippe Moreau
10h00-10h15 Discussion and questions
10h15-10h35 Tea break / Poster viewing
10h35-11h20 Treatment of R/R disease in young patients with MCL – Prof Gianluca Gaidano
11h20-12h05 Treatment options in WM: What to choose when? – Prof Gianluca Gaidano
12h05-12h20 Discussion and questions
12h20-13h20 Lunch / Poster viewing
13h20-15h15 Diffuse large B-cell lymphoma (Sponsored by Roche)
Chair: Dr Pieter De Witt
13h20-14h05 DLBCL: Current standard of care – Dr Andrew Davies
14h05-14h50 DLBCL: Future directions – Dr Andrew Davies
14h50-15h05 Discussion and questions
15h05-15h15 Closing remarks – Dr Hannes Koornhof